Module 21 – The International Comparison
International Module — Module 21 of 21 | Purus Lumina Device Care Education Programme
The International Comparison
The gap is not British. It is global. Purus Lumina is the first entity anywhere to document it.
The Global Picture
Prescribed CBPM programmes are now established in a growing number of jurisdictions across Europe, North America, Australasia, the Middle East, and beyond. Germany. Canada. Australia. Israel. The Netherlands. Portugal. Malta. Luxembourg. New Zealand. Thailand. Each has its own regulatory framework, its own clinical pathway, its own prescription and dispensing infrastructure.
In every one of them, the device is patient-sourced. Unregulated as a medical instrument. Maintained without a documented care standard.
The gap is not a British oversight. It is a global structural failure — replicated across every jurisdiction that has established a CBPM programme without addressing the infrastructure that supports its administration.
Jurisdiction by Jurisdiction
Canada — the world's first G7 nation to legalise cannabis nationally. A mature medical programme with tens of thousands of registered patients. No documented device care standard. No manufacturer protocol. No clinical handover document for device maintenance.
Germany — established a prescribed CBPM programme in 2017; expanded significantly in 2024. One of the fastest-growing markets in Europe. No device care standard. No hygiene protocol. No patient guidance on device maintenance from any regulatory body.
Australia — a regulated CBPM framework with a TGA approval pathway. Thousands of approved prescriptions. No documented standard for device care, cleaning, or maintenance in any TGA guidance document.
Israel — one of the most established prescribed CBPM programmes in the world, with decades of clinical experience. No published device care curriculum. No patient-facing hygiene standard from the Ministry of Health.
The Netherlands — a government-regulated CBPM supply programme (BMC) with pharmacy dispensing. No device care standard. No cleaning protocol. No maintenance guidance.
Portugal, Malta, Luxembourg, New Zealand, Thailand — each with its own legal framework, its own clinical pathway, and the same absence: no documented standard for the care of the device through which the medicine is administered.
The Pattern
The pattern is consistent across every jurisdiction:
- A CBPM programme is established and a clinical pathway is created
- Prescriptions are issued and CBPMs are dispensed
- Patients source their own dry herb devices from consumer markets
- No regulatory body publishes guidance on device care or maintenance
- No manufacturer provides a clinical-standard cleaning protocol
- No prescriber has a handover document to give their patient
- The patient administers a prescribed controlled substance through an unregulated, unmaintained device, without a documented standard for its care
This is not a failure of any single jurisdiction. It is a failure of the global CBPM infrastructure to address a fundamental patient safety question: how should the device through which the medicine is administered be maintained?
The First
Purus Lumina is the first entity anywhere in the world to document, structure, and publish a device care curriculum for patients prescribed CBPMs.
Not a commercial claim. A matter of public record.
This curriculum — 21 modules, five series, published in perpetuity — is the first documented standard of its kind in any jurisdiction. It has been submitted to NICE, MHRA, NHS England, and the Home Office as a formal educational contribution. It is archivable in perpetuity. It exists as part of the public record of what was known, when it was known, and who documented it first.
The gap is global. The documentation is British. The infrastructure response — The Albion Protocol: Sovereign Ground — is the answer.
What This Means
The international comparison establishes three things:
- The device care gap is not a British anomaly — it is a global structural failure replicated across every legalised CBPM jurisdiction
- No other entity in any jurisdiction has documented, structured, and published a device care curriculum before Purus Lumina
- The opportunity to establish the global standard exists now, and it exists here
This curriculum is the foundation. The Albion Protocol: Sovereign Ground is the infrastructure. Together, they represent the first coherent, documented, published response to a gap that exists in every legalised CBPM jurisdiction on earth.
Read: The Albion Protocol: Sovereign Ground →
↑ Return to the Device Care Education Hub
Module 21 is the final module of the Purus Lumina Device Care Curriculum — the world's first documented device care education programme for patients prescribed botanical medicine. Published as a matter of public record. Preserved in perpetuity.
This module was published on 4 July 2026 and exists in perpetuity as part of the Purus Lumina Device Care Curriculum — the world's first documented device care education programme for patients prescribed botanical medicine. It will not be removed.
Glenn Hailes · Director · Purus Lumina Ltd · 3rd Floor, 86–90 Paul Street · London EC2A 4NE · United Kingdom · Registered in England and Wales